欢迎访问西亚试剂!
西亚试剂banner
西亚试剂banner
西亚试剂banner

当前位置:首页 > 新闻中心

西亚试剂:Deregulated Estrogen Receptor and p53 Heterozygosity Colla

发布时间:2025-08-20

Deregulated Estrogen Receptor  and p53 Heterozygosity Collaborate in the Development of Mammary Hyperplasia
Edgar S. Díaz-Cruz1 and Priscilla A. Furth1,2

Both increased estrogen receptor  (ER) expression and germline disruption of one p53 allele increase breast cancer risk in women. Genetically engineered mouse models of deregulated ER expression and p53 haploinsufficiency were used to investigate similarities and differences of each genetic lesion alone and in combination on mammary preneoplasia development. Each genetic lesion independently and in combination led to development of age-dependent preneoplasia, but the highest prevalence was found in compound mice with increased ER expression coupled with p53 heterozygosity. All genetic lesions were associated with extracellular signal-regulated kinase 1/2 activation; however, only p53 heterozygous and compound mice showed increased levels of phosphorylated AKT and decreased p27 expression. The highest levels of cell proliferation were found in compound mice, but increased levels were also found with either increased ER expression or p53 heterozygosity. Mice with increased ER expression showed predicted higher levels of nuclear-localized ER, but this was attenuated in compound mice in association with a relative increase in Src phosphorylation. Parity protection was limited to p53 heterozygous mice and not found in mice with increased ER alone. In summary, increased and deregulated ER collaborates with p53 heterozygosity in increasing the risk of mammary preneoplasia development. Cancer Res; 70(10); 3965–74. ?2010 AACR.

上一篇:西亚试剂 :二苯基氯化磷
下一篇:国内首套青蒿素规模化生产装置建成投产
版权所有:山东西亚化学有限公司

鲁ICP备20015914号-4